Exciting News for Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation is thrilled to announce a significant milestone as the company’s stock has officially resumed trading under the symbol NYMXF on the Over the Counter QB market. This development signifies an important advancement, transitioning to a higher tier from its previous listing, which opens up new possibilities for investors and enhances the company's visibility.
New Opportunities with the OTCQB Listing
The OTCQB listing allows NYMXF to be eligible for proprietary broker-dealer quotations, which is a positive step for Nymox. This change emphasizes the company's commitment to growth and its dedication to providing valuable resources for its shareholders.
Message from Leadership
Paul Averback, the President of Nymox, expressed his enthusiasm stating, “We are delighted that Nymox has now qualified to be on the OTCQB exchange. The Company thanks the professional teams for their guidance, ensuring a smooth transition. Our shareholders have shown remarkable patience and support, and we deeply appreciate all our teammates and friends contributing to Nymox's progress.”
The Importance of Prostate Treatment
Nymox continues to focus on developing innovative treatments, particularly for prostate diseases. As Averback pointed out, there is a pressing need for safer and more effective options for treating prostate ailments. The company is determined to make substantial advancements in this field accessible for public use.
Focus on NYMOZARFEX™
NYMOZARFEX™ is a pivotal product for Nymox, administered through a simple in-office procedure requiring only a few minutes without the need for anesthesia. It's targeted at conditions such as benign prostatic hyperplasia (BPH) and early-stage prostate cancer, backed by robust clinical trials involving over 1750 patients. With more than 1200 administrations, NYMOZARFEX™ has demonstrated notable safety and effectiveness, positioned as a transformative treatment in the prostate health sector.
Commitment to Innovation and Transparency
As a forward-thinking company, Nymox is dedicated to maintaining transparency and fostering engagements with its stakeholder community. For deeper insights into Nymox and their initiatives, interested parties are encouraged to reach out through the company contact information available, ensuring that communication remains open.
Frequently Asked Questions
What is the significance of Nymox's listing on the OTCQB?
The OTCQB listing enhances the visibility of Nymox and provides access to a broader range of investors while opening avenues for proprietary broker-dealer quotations.
What treatments are associated with Nymox?
Nymox focuses on developing powerful treatments for prostate diseases, specifically through their product NYMOZARFEX™, targeted towards patients with BPH and early-stage prostate cancer.
How does NYMOZARFEX™ work?
NYMOZARFEX™ is given in a quick in-office procedure and has shown a significant safety profile without common side effects typically seen in other BPH treatments.
How can I contact Nymox for more information?
You can reach Nymox Pharmaceutical Corporation at 1-800-93NYMOX or via email at info@nymox.com for further inquiries.
Why is Nymox focused on prostate disease treatments?
The company recognizes a critical need for safer and more effective options in prostate disease management, aiming to address unfulfilled medical needs in this area.
